TheEdgeResearch
Home / Stocks / AIM

AIM ImmunoTech Inc. (AIM)

AMEX Healthcare Biotechnology
$0.44 ▲ +8.59%
Market Cap
$1.5M
Sector
Healthcare
Industry
Biotechnology
Beta
1.24
52-Wk Range
0.21-19.73812
CEO
Thomas K. Equels
Country
US
Currency
USD

AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its p…

Open full interactive analysis & DCF →